Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goldhirsch

Showing results (531-540 of 573) with videos related to

Pageof 58
Sort By:
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Cancer|March 26, 2003
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial VVito J Spataro, Heather Litman, Giuseppe Viale, et al.
Breast (Edinburgh, Scotland)|February 10, 2015
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?Olivia Pagani, Monica Ruggeri, Silvia Manunta, et al.
Lancet (London, England)|January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Marion Procter, Richard D Gelber, et al.
Breast Cancer Research and Treatment|November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Breast (Edinburgh, Scotland)|July 31, 2019
Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European CentersM Ruggeri, E Pagan, V Bagnardi, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Pageof 58

Showing results (531-540 of 573) with videos related to

Sort By:
Pageof 58
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Cancer|March 26, 2003
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial VVito J Spataro, Heather Litman, Giuseppe Viale, et al.
Breast (Edinburgh, Scotland)|February 10, 2015
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?Olivia Pagani, Monica Ruggeri, Silvia Manunta, et al.
Lancet (London, England)|January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Marion Procter, Richard D Gelber, et al.
Breast Cancer Research and Treatment|November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Breast (Edinburgh, Scotland)|July 31, 2019
Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European CentersM Ruggeri, E Pagan, V Bagnardi, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Pageof 58